Beneficial nutraceutical modulation of cerebral erythropoietin expression and oxidative stress: An experimental study

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 2, 2011, Pages 187-194

  Sedriep, S ^a   Xia, X ^b   Marotta, F ^c   Zhou, L ^d   Yadav, H ^e   Yang, H ^d   Soresi, V ^f   Catanzaro, R ^g   Zhong, K ^d   Polimeni, A ^c   Chui, D H ^d  

^a Bio Cell Unit Lab and Analysis Center   (Japan)

^b GUILIN MEDICAL UNIVERSITY   (China)

^c ReGenera Research Group for Aging Intervention   (Italy)

^d PEKING UNIVERSITY   (China)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Octopus Scientific Association of Bio Prevention   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

Author keywords

Brain cognitive impairment; Erythropoietin; Oxidative stress; Phycocyanins; Prematurely senescent mice

Indexed keywords

AMINO ACID; ANTIOXIDANT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; KLAMIN; MALONALDEHYDE; NUTRACEUTICAL; PHENETHYLAMINE; PHYCOCYANIN; PHYTOCHROME; THIOL; UNCLASSIFIED DRUG; PHENETHYLAMINE DERIVATIVE; THIOL DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APHANIZOMENON; ARTICLE; BODY WEIGHT; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL STUDY; FOOD INTAKE; LEARNING; LOW DRUG DOSE; MAZE TEST; MEMORY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENESCENCE; UPREGULATION; WESTERN BLOTTING; AGING; ANIMAL; ANIMAL MODEL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; BRAIN; DIET SUPPLEMENTATION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

ALGAE; ANIMALIA; APHANIZOMENON FLOS-AQUAE; MUS;

ADMINISTRATION, ORAL; AGING; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; BRAIN; DIETARY SUPPLEMENTS; ERYTHROPOIETIN; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; OXIDATIVE STRESS; PHENETHYLAMINES; PHYCOCYANIN; PHYTOCHROME; RECEPTORS, ERYTHROPOIETIN; SULFHYDRYL COMPOUNDS; UP-REGULATION;

EID: 80052891625     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wojchowski DM, Menon MP, Sathyanarayana P, Fang J, Karur V, Houde E, Kapelle W, Bogachev O. Erythropoietin-dependent erythropoiesis: New insights and questions. Blood Cells Mol Dis 2006; 36:232-38.
2. Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus Kinase-Signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 Rats. Pediatr Res 2005; 57:481-87. (Pubitemid 40389334)
3. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 2007; 282:25875-83. (Pubitemid 47372832)
4. Wallach I, Zhang J, Hartmann A, van Landeghem FK, Ivanova A, Klar M, Dame C. Erythropoietin-receptor gene regulation in neuronal cells. Pediatr Res 2009; 65:619-24.
5. Park MH, Lee SM, Lee JW, et al. ERK-mediated production of neurotrophic factors by astrocytes promotes neuronal stem cell differentiation by erythropoietin. Biochem Biophys Res Commun 2006; 339:1021-28. (Pubitemid 41790566)
6. Assaraf MI, Diaz Z, Liberman A, Miller WH Jr, Arvanitakis Z, Li Y, Bennett DA, Schipper HM. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol 2007; 66:389-98. (Pubitemid 46701321)
7. Jun Y, JiangTao X, YuanGui H, et al. Erythropoietin pre-treatment prevents cognitive impairments following status epilepticus in rats. Brain Res 2009; 1282:57-66.
8. Sättler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bähr M, Diem R. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11:181-92.
9. Ehrenreich H, Weissenborn K, Prange H, et al. EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40:647-56.
10. Shein NA, Grigoriadis N, Alexandrovich AG, Simeonidou C, Spandou E, Tsenter J, Yatsiv I, Horowitz M, Shohami E. Differential neuroprotective properties of endogenous and exogenous erythropoietin in a mouse model of traumatic brain injury. J Neurotrauma 2008; 25:112-23. (Pubitemid 351252576)
11. Grasso G, Graziano F, Sfacteria A, et al. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery 2009; 65:763-69.
12. Li Y, Lu Z, Keogh CL, Yu SP, Wei L. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 2007; 27:1043-54. (Pubitemid 46659037)
13. Chi OZ, Hunter C, Liu X, Weiss HR. Effects of erythropoietin on blood-brain barrier disruption in focal cerebral ischemia. Pharmacology 2008; 82:38-42. (Pubitemid 351931408)
14. Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, Reina M, Vilaró S, Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003; 18:2538-44. (Pubitemid 37452669)
15. Wang Y, Kilic E, Kilic U, et al. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 2005; 128:52-63. (Pubitemid 40070520)
16. Glade MJ. Oxidative stress and cognitive longevity. Nutrition 2010; 26:595-603.
17. Shih PH, Chan YC, Liao JW, Wang MF, Yen GC. Antioxidant and cognitive promotion effects of anthocyanin-rich mulberry (Morus atropurpurea L.) on senescence-accelerated mice and prevention of Alzheimer's disease. J Nutr Biochem 2009; 21:598-605.
18. Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S, Ahmad A, Shrivastav P, Islam F. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 2009; 1281:117-27.
19. Chan YC, Hosoda K, Tsai CJ, Yamamoto S, Wang MF. Favorable effects of tea on reducing the cognitive deficits and brain morphological changes in senescence-accelerated mice. J Nutr Sci Vitaminol (Tokyo) 2006; 52:266-73. (Pubitemid 44520055)
20. De La Fuente M, MĩNano M, Victor VM. Relation between exploratory activity and immune function in aged mice: a preliminary study. Mech Ageing Dev 1998; 102:263-77. (Pubitemid 28353544)
21. Inwang EE, Mosnaim AD, Sabelli HC. Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem 1973; 20:1469-73.
22. Bhat VB, Madyastha KM. C-phycocyanin, a potent peroxyl radical scavenger in vivo and in vitro. Biochem Biophys Res Commun 2000; 275:20-25. (Pubitemid 30663622)
23. Romay C, Armesto J, Remirez D, González R, Ledon N, García I. Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res 1998; 47:36-41. (Pubitemid 28048114)
24. Benedetti S, Benvenuti F, Pagliarani S, Francogli S, Scoglio S, Canestrari F. Antioxydant properties of a novel phycocyanin extract from the blue-green alga Aphanizomenon Flos Aquae. Life Sci 2004; 75:2353-62. (Pubitemid 39180042)
25. Scoglio S, Benedetti S, Canino C, Santagni S, Rattighieri E, Chierchia E, Canestrari F, Genazzani AD. Effect of a 2-month treatment with Klamin, a Klamath algae extract, on the general well-being, antioxidant profile and oxidative status of postmenopausal women. Gynecol Endocrinol 2009; 25:235-40.
26. McClure MM, Threlkeld SW, Fitch RH. Auditory processing and learning/memory following erythropoietin administration in neonatally hypoxic-ischemic injured rats. Brain Res 2007; 1132:203-09. (Pubitemid 46096444)
27. Chen ZY, Warin R, Noguchi CT. Erythropoietin and normal brain development: Receptor expression determines multi-tissue response. Neurodegener Dis 2006; 3:68-75. (Pubitemid 43760371)
28. Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 2007; 61:671-75. (Pubitemid 46800274)
29. Minnerup J, Heidrich J, Rogalewski A, Schäbitz WR, Wellmann J. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009; 40:3113-20.
30. Keogh CL, Yu SP, Wei L. The effect of recombinant human erythropoietin on neurovasculature repair after focal ischemic stroke in neonatal rats. J Pharmacol Exp Ther 2007; 322:521-28. (Pubitemid 47105803)
31. Buhrer C, Felderhoff-Mueser U, Wellmann S. Erythropoietin and ischemic conditioning- why two good things may be bad. Acta Paediatr 2007; 96:787-89. (Pubitemid 46846920)
32. Weber A, Dzietko M, Berns M, et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis 2005; 20:594-600. (Pubitemid 41476285)
33. Mogensen J, Jensen C, Kingod SC, Hansen A, Larsen JA, Mala H. Erythropoietin improves spatial delayed alternation in a T-maze in fimbria-fornix transected rats. Behav Brain Res 2008; 186:215-21. (Pubitemid 350122753)
34. Jun Y, JiangTao X, YuanGui H, et al. Erythropoietin pre-treatment prevents cognitive impairments following status epilepticus in rats. Brain Res 2009; 1282:57-66.
35. Sanchez PE, Fares RP, Risso JJ, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci USA 2009; 106:9848-53.
36. Hussein MH, Daoud GA, Kakita H, et al. High cerebrospinal fluid antioxidants and interleukin 8 are protective of hypoxic brain damage in newborns. Free Radic Res 2010; 44:422-9.
37. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 2007; 282:25875-83. (Pubitemid 47372832)